Session6A
Session6A
Session6A
2
Probability that the market will go up (or
down)…
¨ There were 1257 trading days between January 1, 2016 and December
31, 2020. Over that period, the S&P 500 was
¤ Up on 700 trading days
¤ Down on 557 trading days
¨ Based upon that data, the probability that the market was up during the
period was 55.69% and the probability that the market was down was
44.31%.
¨ Can you use this to accept or reject the hypothesis that there was a 50%
chance of up/down days., at least during this period?
!.#∗!.#
¤ Std Error in probability, if random = = 0.0141 or 1.41%
(+#,
¤ Range with 95% confidence, on up probability = 0.5569 ±2 .0141 : Range: 52.87%
to 58.51% probability of up (or down) days, during this period
¤ At least during this period, you can reject the 50:50 up/down hypothesis.
¨ Can you extrapolate from this that there will be more up than down days
in the market in the future?
3
Conditional Probabilities…
4
Cumulative Probabilities…
5
2. Transition Probabilities
6
Money Manager Performance
2011
3. Probability of Corporate Default
2012
2013
2014
2015
2016
2017
2018
2019
2020
8
Conditional Probabilities: Bond Ratings
and Default Rates
9
A Multiple Discriminant Model of Default:
The Altman Z Score
Altman analyzed 66
manufacturing companies, of
which 33 became bankrupt
within the years 1946- 1965
and the other half were
existing companies in 1966.
10
A Probit Model: Hostile Acquisitions
11
Source: Hostility in Takeovers: In the Eyes of the Beholder, G.W. Schwert, JF 2000
3. Decision Tree: An Example
¨ Consider a pharmaceutical drug for treating Type 1 diabetes that has gone
through preclinical testing and is about to enter phase 1 of the FDA approval
process.
¤ Phase 1 is expected to cost $ 50 million and will involve 100 volunteers to determine safety
and dosage; it is expected to last 1 year. There is a 70% chance that the drug will successfully
complete the first phase.
¤ In phase 2, the drug will be tested on 250 volunteers for effectiveness in treating diabetes over
a two-year period. This phase will cost $ 100 million and the drug will have to show a
statistically significant impact on the disease to move on to the next phase. There is only a 30%
chance that the drug will prove successful in treating type 1 diabetes but there is a 10% chance
that it will be successful in treating both type 1 and type 2 diabetes and a 10% chance that it
will succeed only in treating type 2 diabetes.
¤ In phase 3, the testing will expand to 4,000 volunteers to determine the long-term
consequences of taking the drug. If the drug is tested on only type 1 or type 2 diabetes
patients, this phase will last 4 years and cost $ 250 million; there is an 80% chance of success.
If it is tested on both types, the phase will last 4 years and cost $ 300 million; there is a 75%
chance of success.
¨ If the drug passes through all 3 phases, the costs and annual cash flows are below:
Disease treatment Cost of Development Annual Cash Flow
Type 1 diabetes only $ 500 million $ 300 million for 15 years
Type 2 diabetes only $ 500 million $ 125 million for 15 years
Type 1 and 2 diabetes $ 600 million $ 400 million for 15 years
13
The Tree…
14
The Fold Back
15
4. Scenario Analysis: easyJet and Brexit in
2019
16
Expected Value per share = .25 (£12.02) + .50 (£15.70) + .25 (£19.38) = £15.70
Aswath Damodaran
16